HCV Product Pipeline
 | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
| Discovery Preclinical Phase 1 Phase 2 Phase 3 | ||||||
| Compounds | ||||||
| ACH-3102NS5A Inhibitor | ||||||
| ACH-2684NS3/4A Protease Inhibitor | ||||||
| SovaprevirNS3/4A Protease Inhibitor | ||||||
| ACH-3422Nucleotide NS5B Polymerase Inhibitor | ||||||
About Achillion
Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.
HCV Education
About the Hepatitis C Virus
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
No upcoming events at this time.
